Maxwell engineers technologies designed to create health for the world, safely and affordably. We are currently focused on Alzheimer’s Disease, and have several candidate drugs and therapies which have proven successful in mouse studies at Stanford and are now entering human clinical trials.
The patent-pending therapeutic plasma exchange protocol that uses an optimized plasma product as a new Alzheimer’s biologic drug.
Health Anonymous, a division of MaxWell Biosciences, is the world’s first and largest curated, young donor plasma registry. These unknown heroes enable MaxWell to pioneer novel therapies and empower the world to act on chronic health issues.